Toru Suzuki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Toru Suzuki has a total of 654 co-authors. Here are the top co-authors by number of shared publications:
Kenichi Aizawa
Division of Clinical Pharmacology, Department of Pharmacology, Jichi Medical University , Tochigi
25 shared publicationsRyozo Nagai
Jichi Medical University School of Medicine, Shimotsuke, Japan
25 shared publications- Andrea Salzano
Department of Translational Medical Sciences, Federico II University, Naples, Italy
13 shared publications - Daigo Sawaki
INSERM U955, Université Paris-Est Creteil (UPEC), 51 Av de Lattre de Tassigny, 94100 Créteil, France
13 shared publications - Liam Michael Heaney
School of Sport, Exercise and Health Sciences Loughborough University Loughborough UK
13 shared publications - Muhammad Zubair Israr
Department of Cardiovascular Sciences, University of Leicester and NIHR Leicester Biomedical Research Centre, Glenfield Hospital , LE3 9QP Leicester
12 shared publications
Latest Publications
- Open Access
- 16 May 2026
- Published by Elsevier in JACC: Asia
- Vol. 6 (10) , 2557-2561
Toward Cardiovascular Digital Twins in Japan
- 16 May 2026
- Published by Elsevier in JACC: Asia
- Vol. 6 (10) , 2557-2561
Open AccessToward Cardiovascular Digital Twins in Japan
- Open Access
- 26 March 2026
- Published by OAE Publishing Inc. in Microbiome Research Reports
- Vol. 5 (1)
Development of a multi-targeted metabolomics platform for semi-quantification of faecal metabolites: a proof-of-concept analysis in human faeces
Objectives: Targeted metabolomic analysis of faecal samples has been limited by narrow chemical coverage. Here, we established a multiplexed, triple quadrupole mass spectrometry (TQMS)-based targeted metabolomics workflow. This workflow allows accurate detection and semi-quantification of diverse faecal metabolites and provides a methodological platform for studying host-microbiome metabolic interactions. Methods: Faecal metabolomes from germ-free (GF) mice, ex-germ-free (Ex-GF) mice, and human participants were analysed using TQMS-based targeted metabolomics. The analysis comprised multiple methods targeting amino acids and their derivatives, carbohydrates, short-chain fatty acids, bile acids, lipid mediators, and phospholipids. Results: In total, 607 low-molecular-weight metabolites in 44 chemical categories were detected and semi-quantified. Faecal metabolomes of GF and Ex-GF mice were analysed, uncovering 341 intestinal microbiome-dependent metabolites. A proof-of-concept analysis using faecal samples from five patients with colorectal cancer demonstrated the successful application of this platform to human clinical material, highlighting its strong potential for future disease-oriented metabolomic investigations. Conclusion: We developed a multi-targeted faecal metabolomics platform that substantially expands the chemical space accessible to targeted analysis. This workflow provides a methodological foundation for future large-scale and translational studies.
- 26 March 2026
- Published by OAE Publishing Inc. in Microbiome Research Reports
- Vol. 5 (1)
Open AccessDevelopment of a multi-targeted metabolomics platform for semi-quantification of faecal metabolites: a proof-of-concept analysis in human faeces
Objectives: Targeted metabolomic analysis of faecal samples has been limited by narrow chemical coverage. Here, we established a multiplexed, triple quadrupole mass spectrometry (TQMS)-based targeted metabolomics workflow. This workflow allows accurate detection and semi-quantification of diverse faecal metabolites and provides a methodological platform for studying host-microbiome metabolic interactions. Methods: Faecal metabolomes from germ-free (GF) mice, ex-germ-free (Ex-GF) mice, and human participants were analysed using TQMS-based targeted metabolomics. The analysis comprised multiple methods targeting amino acids and their derivatives, carbohydrates, short-chain fatty acids, bile acids, lipid mediators, and phospholipids. Results: In total, 607 low-molecular-weight metabolites in 44 chemical categories were detected and semi-quantified. Faecal metabolomes of GF and Ex-GF mice were analysed, uncovering 341 intestinal microbiome-dependent metabolites. A proof-of-concept analysis using faecal samples from five patients with colorectal cancer demonstrated the successful application of this platform to human clinical material, highlighting its strong potential for future disease-oriented metabolomic investigations. Conclusion: We developed a multi-targeted faecal metabolomics platform that substantially expands the chemical space accessible to targeted analysis. This workflow provides a methodological foundation for future large-scale and translational studies.
- Open Access
- 3 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (5) , e037506
Sex‐Related Differences in Clinical Profile, Management, and Outcomes of Patients With Type A and B Acute Aortic Dissection: Observations From IRAD
Background: Available data about sex differences in patients with acute aortic dissection (AAD) are scant and conflicting. The aim of this study is to assess sex‐related differences in clinical characteristics, presentation, diagnostic findings, management, and outcomes among patients with type A (TA‐AAD) and type B AAD (TB‐AAD). Methods: Data about 11 586 patients enrolled in the IRAD (International Registry of Acute Aortic Dissection) from 1996 to 2022, were analyzed; 7819 (67.5%) experienced TA‐AAD and 3867 (33.0%) TB‐AAD. Men and women were compared with regard to diagnosis, treatment, and in‐hospital and long‐term survival. Results: One third of patients were women (TA‐AAD, 34.4%; and TB‐AAD, 34.5%). Women were older than men for both types of AAD. The median time from hospital admission to diagnosis was longer in women for both TA‐AAD and TB‐AAD ( P P P P P P =0.23). No difference in overall ( P =1), medical ( P =0.38), endovascular ( P =1), and surgical ( P =0.51) mortality rates was observed for TB‐AAD between men and women. After TA‐AAD, women showed lower 4‐year survival compared with men (81.4% versus 86.6%, P <0.001). Conclusions: The present study highlights important sex‐related differences in AAD; there is a need to design tailored aortic disease management programs to improve outcomes in women.
- 3 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (5) , e037506
Open AccessSex‐Related Differences in Clinical Profile, Management, and Outcomes of Patients With Type A and B Acute Aortic Dissection: Observations From IRAD
Background: Available data about sex differences in patients with acute aortic dissection (AAD) are scant and conflicting. The aim of this study is to assess sex‐related differences in clinical characteristics, presentation, diagnostic findings, management, and outcomes among patients with type A (TA‐AAD) and type B AAD (TB‐AAD). Methods: Data about 11 586 patients enrolled in the IRAD (International Registry of Acute Aortic Dissection) from 1996 to 2022, were analyzed; 7819 (67.5%) experienced TA‐AAD and 3867 (33.0%) TB‐AAD. Men and women were compared with regard to diagnosis, treatment, and in‐hospital and long‐term survival. Results: One third of patients were women (TA‐AAD, 34.4%; and TB‐AAD, 34.5%). Women were older than men for both types of AAD. The median time from hospital admission to diagnosis was longer in women for both TA‐AAD and TB‐AAD ( P P P P P P =0.23). No difference in overall ( P =1), medical ( P =0.38), endovascular ( P =1), and surgical ( P =0.51) mortality rates was observed for TB‐AAD between men and women. After TA‐AAD, women showed lower 4‐year survival compared with men (81.4% versus 86.6%, P <0.001). Conclusions: The present study highlights important sex‐related differences in AAD; there is a need to design tailored aortic disease management programs to improve outcomes in women.
- Open Access
- 26 February 2026
- Published by Elsevier in JACC: Asia
- Vol. 6 (10) , 2439-2454
Artificial Intelligence and Digital Innovation in Cardiovascular Medicine
- 26 February 2026
- Published by Elsevier in JACC: Asia
- Vol. 6 (10) , 2439-2454
Open AccessArtificial Intelligence and Digital Innovation in Cardiovascular Medicine
- Open Access
Epigenetic Programming of Macrophage Phenotypes by STING–IRF3 Drives Inflammation in Ascending Thoracic Aortic Dissection
Background: Ascending thoracic aortic dissection (ATAD) is characterized by extensive macrophage (MΦ) accumulation and profound inflammation; however, the mechanisms sustaining pro-inflammatory MΦ activation remain incompletely defined. Emerging evidence indicates that epigenetically generated immune memory drives innate immune cells toward persistent inflammatory states. In this study, we investigated whether epigenetic reprogramming governs MΦ phenotypic fate and contributes to ATAD pathogenesis. Methods: We performed single-cell RNA sequencing of human ascending aortic tissues from controls, patients with ascending thoracic aortic aneurysm (ATAA), and patients with acute ascending thoracic aortic dissection (ATAD). We also performed integrated single-cell RNA sequencing, single-cell ATAC sequencing, and spatial transcriptomics in an angiotensin II (Ang II)–infused mouse model. The role of the STING–IRF3 signaling axis in MΦ epigenetic programming was examined using MΦ- Sting -/- and MΦ- Irf3 -/- mice. Results: In human and mouse aortic tissues, we identified multiple functional MΦ populations including pro-inflammatory, phagocytic/anti-inflammatory, proliferative, and reparative/healing MΦs. Aortic MΦs in both sporadic ATAD patients and Ang II–induced ATAD mice exhibited a pronounced pro-inflammatory bias with enhanced differentiation toward pro-inflammatory MΦs and impaired differentiation toward phagocytic/anti-inflammatory states. Pro-inflammatory MΦs were particularly abundant in dissection sites, whereas phagocytic MΦs were enriched in discrete adventitial niches. Origin analyses revealed a substantial increase in CCR2 ⁺ recruited MΦs within the aortic wall, which preferentially differentiated into pro-inflammatory MΦs. In contrast, LYVE1 ⁺ resident MΦs— predominantly biased toward phagocytic phenotypes—were markedly depleted in ATAD. Single-cell ATAC sequencing identified coordinated chromatin remodeling with increased accessibility at pro-inflammatory gene loci and decreased accessibility at phagocytic gene loci. Among candidate transcriptional regulators identified, IRF family TFs, including IRF3 emerged as unique factors capable of simultaneously promoting pro-inflammatory gene programs while suppressing phagocytic gene expression. Mechanistically, STING–IRF3 signaling orchestrates this biased transcriptional state, likely through coordinated BRG1-dependent chromatin opening at pro-inflammatory gene loci and chromatin closing at phagocytic/anti-inflammatory gene loci. MΦ specific Sting -/- and Irf3 -/- mice exhibited attenuated inflammatory reprogramming and reduced aortic destruction and dissection. Conclusions: These findings identify STING–IRF3–mediated epigenetic programming of MΦs as a fundamental mechanism driving aortic inflammation and ATAD development. Targeting MΦ epigenetic programming may represent a promising therapeutic strategy to prevent aortic dissection. Graphic
Open AccessEpigenetic Programming of Macrophage Phenotypes by STING–IRF3 Drives Inflammation in Ascending Thoracic Aortic Dissection
Background: Ascending thoracic aortic dissection (ATAD) is characterized by extensive macrophage (MΦ) accumulation and profound inflammation; however, the mechanisms sustaining pro-inflammatory MΦ activation remain incompletely defined. Emerging evidence indicates that epigenetically generated immune memory drives innate immune cells toward persistent inflammatory states. In this study, we investigated whether epigenetic reprogramming governs MΦ phenotypic fate and contributes to ATAD pathogenesis. Methods: We performed single-cell RNA sequencing of human ascending aortic tissues from controls, patients with ascending thoracic aortic aneurysm (ATAA), and patients with acute ascending thoracic aortic dissection (ATAD). We also performed integrated single-cell RNA sequencing, single-cell ATAC sequencing, and spatial transcriptomics in an angiotensin II (Ang II)–infused mouse model. The role of the STING–IRF3 signaling axis in MΦ epigenetic programming was examined using MΦ- Sting -/- and MΦ- Irf3 -/- mice. Results: In human and mouse aortic tissues, we identified multiple functional MΦ populations including pro-inflammatory, phagocytic/anti-inflammatory, proliferative, and reparative/healing MΦs. Aortic MΦs in both sporadic ATAD patients and Ang II–induced ATAD mice exhibited a pronounced pro-inflammatory bias with enhanced differentiation toward pro-inflammatory MΦs and impaired differentiation toward phagocytic/anti-inflammatory states. Pro-inflammatory MΦs were particularly abundant in dissection sites, whereas phagocytic MΦs were enriched in discrete adventitial niches. Origin analyses revealed a substantial increase in CCR2 ⁺ recruited MΦs within the aortic wall, which preferentially differentiated into pro-inflammatory MΦs. In contrast, LYVE1 ⁺ resident MΦs— predominantly biased toward phagocytic phenotypes—were markedly depleted in ATAD. Single-cell ATAC sequencing identified coordinated chromatin remodeling with increased accessibility at pro-inflammatory gene loci and decreased accessibility at phagocytic gene loci. Among candidate transcriptional regulators identified, IRF family TFs, including IRF3 emerged as unique factors capable of simultaneously promoting pro-inflammatory gene programs while suppressing phagocytic gene expression. Mechanistically, STING–IRF3 signaling orchestrates this biased transcriptional state, likely through coordinated BRG1-dependent chromatin opening at pro-inflammatory gene loci and chromatin closing at phagocytic/anti-inflammatory gene loci. MΦ specific Sting -/- and Irf3 -/- mice exhibited attenuated inflammatory reprogramming and reduced aortic destruction and dissection. Conclusions: These findings identify STING–IRF3–mediated epigenetic programming of MΦs as a fundamental mechanism driving aortic inflammation and ATAD development. Targeting MΦ epigenetic programming may represent a promising therapeutic strategy to prevent aortic dissection. Graphic
- Open Access
- 2 December 2025
- Published by Elsevier in JACC: Asia
- Vol. 5 (12) , 1634-1637
Association of Gut Microbiome Biomarkers With Mortality in Chinese Patients With Acute/Worsening Heart Failure
- 2 December 2025
- Published by Elsevier in JACC: Asia
- Vol. 5 (12) , 1634-1637
Open AccessAssociation of Gut Microbiome Biomarkers With Mortality in Chinese Patients With Acute/Worsening Heart Failure
- Open Access
- 2 December 2025
- Published by Elsevier in JACC: Asia
- Vol. 5 (12) , 10-11
Heart Failure: Comorbidities/Multimorbidities
- 2 December 2025
- Published by Elsevier in JACC: Asia
- Vol. 5 (12) , 10-11
Open AccessHeart Failure: Comorbidities/Multimorbidities
- 1 May 2025
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 45 (5) , 609-631
Recommendations for Design, Execution, and Reporting of Studies on Experimental Thoracic Aortopathy in Preclinical Models
There is a recent dramatic increase in research on thoracic aortic diseases that includes aneurysms, dissections, and rupture. Experimental studies predominantly use mice in which aortopathy is induced by chemical interventions, genetic manipulations, or both. Many parameters should be deliberated in experimental design in concert with multiple considerations when providing dimensional data and characterization of aortic tissues. The purpose of this review is to provide recommendations on guidance in (1) the selection of a mouse model and experimental conditions for the study, (2) parameters for standardizing detection and measurements of aortic diseases, (3) meaningful interpretation of characteristics of diseased aortic tissue, and (4) reporting standards that include rigor and transparency.
- 1 May 2025
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 45 (5) , 609-631
Recommendations for Design, Execution, and Reporting of Studies on Experimental Thoracic Aortopathy in Preclinical Models
There is a recent dramatic increase in research on thoracic aortic diseases that includes aneurysms, dissections, and rupture. Experimental studies predominantly use mice in which aortopathy is induced by chemical interventions, genetic manipulations, or both. Many parameters should be deliberated in experimental design in concert with multiple considerations when providing dimensional data and characterization of aortic tissues. The purpose of this review is to provide recommendations on guidance in (1) the selection of a mouse model and experimental conditions for the study, (2) parameters for standardizing detection and measurements of aortic diseases, (3) meaningful interpretation of characteristics of diseased aortic tissue, and (4) reporting standards that include rigor and transparency.
- Open Access
- 28 April 2025
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 33 (2) , 202-211
Risk calculator of multimorbid risk of rehospitalization and death from heart failure: including the contribution of the gut microbiome
Aims: The elucidation of the contributory role of multimorbidity to heart failure (HF) including the gut–heart axis has added a new dimension to our understanding of HF pathophysiology that is not reflected in currently available risk scores. The present investigation aimed to develop and validate a novel risk score model of multimorbidity for HF risk stratification. Methods and results: A risk model was developed based on the contribution of markers associated with HF multimorbidities on outcomes of mortality and/or rehospitalization due to HF (death/HF) at one year. Two independent HF cohorts were combined and randomly split 70:30 using a split-sample validation approach for training and validation cohorts that were not significantly different for investigated variables. Backward logistic regression was used to develop the risk model with a further scoring system to create a simple risk calculator. A final 11-variable risk model (age, previous HF hospitalization, NYHA group III/IV, NT-proBNP, diastolic blood pressure, loop diuretic use, beta-blocker non-use, creatinine, COPD, diabetes, and combined gut metabolites) showed a diagnostic performance of 0.71 in the training cohort (C-statistic validation cohort, 0.70, P < 0.001). A risk score/calculator was further developed based on this model with categorization into three (low-, mid-, and high-) and two (low- and high-) risk groups, with both approaches demonstrating increased incidence of death/HF in patients at the highest risk (P < 0.001). Conclusion: A novel risk model and score were derived that showed the contribution of comorbidities including the added value of the gut–heart axis on risk stratification of HF patients on rehospitalization and death. Lay summary: The contributory role of multimorbidity is not well understood in heart failure (HF), including the more recent addition of the gut microbiome (gut–heart axis). However, in current HF risk scores, the contributory role of multimorbidity is seldom considered. In this study, we developed an 11-variable risk model and a simple risk score calculator for clinical use that considers the contribution of HF multimorbidity, including the gut microbiome. The clinical risk score was developed and validated in a clinical cohort from two combined independent European studies from inpatient heart failure subjects. The outcomes were death due to HF and/or rehospitalization at 1 year. The final model showed diagnostic performance comparable to current HF risk scores. Furthermore, the risk score calculator, developed for clinical use, is able to stratify patients into low-, mid-, and high-risk groups, with worsening outcomes seen with increasing risk group. The importance and novelty of this risk model over current HF risk scores are the contribution of comorbidities including the added value of the gut–heart axis on HF risk stratification.
- 28 April 2025
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 33 (2) , 202-211
Open AccessRisk calculator of multimorbid risk of rehospitalization and death from heart failure: including the contribution of the gut microbiome
Aims: The elucidation of the contributory role of multimorbidity to heart failure (HF) including the gut–heart axis has added a new dimension to our understanding of HF pathophysiology that is not reflected in currently available risk scores. The present investigation aimed to develop and validate a novel risk score model of multimorbidity for HF risk stratification. Methods and results: A risk model was developed based on the contribution of markers associated with HF multimorbidities on outcomes of mortality and/or rehospitalization due to HF (death/HF) at one year. Two independent HF cohorts were combined and randomly split 70:30 using a split-sample validation approach for training and validation cohorts that were not significantly different for investigated variables. Backward logistic regression was used to develop the risk model with a further scoring system to create a simple risk calculator. A final 11-variable risk model (age, previous HF hospitalization, NYHA group III/IV, NT-proBNP, diastolic blood pressure, loop diuretic use, beta-blocker non-use, creatinine, COPD, diabetes, and combined gut metabolites) showed a diagnostic performance of 0.71 in the training cohort (C-statistic validation cohort, 0.70, P < 0.001). A risk score/calculator was further developed based on this model with categorization into three (low-, mid-, and high-) and two (low- and high-) risk groups, with both approaches demonstrating increased incidence of death/HF in patients at the highest risk (P < 0.001). Conclusion: A novel risk model and score were derived that showed the contribution of comorbidities including the added value of the gut–heart axis on risk stratification of HF patients on rehospitalization and death. Lay summary: The contributory role of multimorbidity is not well understood in heart failure (HF), including the more recent addition of the gut microbiome (gut–heart axis). However, in current HF risk scores, the contributory role of multimorbidity is seldom considered. In this study, we developed an 11-variable risk model and a simple risk score calculator for clinical use that considers the contribution of HF multimorbidity, including the gut microbiome. The clinical risk score was developed and validated in a clinical cohort from two combined independent European studies from inpatient heart failure subjects. The outcomes were death due to HF and/or rehospitalization at 1 year. The final model showed diagnostic performance comparable to current HF risk scores. Furthermore, the risk score calculator, developed for clinical use, is able to stratify patients into low-, mid-, and high-risk groups, with worsening outcomes seen with increasing risk group. The importance and novelty of this risk model over current HF risk scores are the contribution of comorbidities including the added value of the gut–heart axis on HF risk stratification.
- Open Access
- 29 May 2024
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 38 (7) , 108779
Tirzepatide ameliorates eating behaviors regardless of prior exposure to glucagon-like peptide receptor agonists in Japanese patients with type 2 diabetes mellitus
- 29 May 2024
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 38 (7) , 108779
Open AccessTirzepatide ameliorates eating behaviors regardless of prior exposure to glucagon-like peptide receptor agonists in Japanese patients with type 2 diabetes mellitus